Henagliflozin for the overweight or obese patients with type 2 diabetes and heart failure: a multicenter, randomized, double-blind, controlled trial

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2024
This article has no abstract
Epistemonikos ID: 07153e9f8ea9c2851ec7a46713eba0f34e230f33
First added on: Apr 08, 2025